Diagnostic MicroRNA markers to screen for sporadic human colon cancer in blood

Cancer Genomics and Proteomics

Volumn 9, Issue 4, 2012, Pages 179-192

  Ahmed, Farid E ^a,c   Amed, Nancy C ^c   Vos, Paul W ^a   Bonnerup, Chris ^a   Atkins, James N ^d   Casey, Michelle ^d   Nuovo, Gerard J ^e   Naziri, Wade ^f   Wiley, John E ^b   Allison, Ron R ^a,g  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c GEM Tox Labs   (United States)

^d Southestern Medical Oncology Center   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f Southern Surgical   (United States)

^g 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Adenocarcinoma; Bioinformatics; Gene expression; LCM; MGB; Microarrays; MicroRNA; MiRNAs; Non invasive diagnosis; Primers; Probes; QC; RNA; RT qPCR; Screening test; Staging; Statistics

Indexed keywords

MICRORNA; MICRORNA 124; MICRORNA 146A; MICRORNA 17 3P; MICRORNA 20A; MICRORNA 21; MICRORNA 214; MICRORNA 222; MICRORNA 7; MIRNA 127 3P; MIRNA 138; MIRNA 183; MIRNA 196A; MIRNA 92A; MIRNA 96; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON POLYPOSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MICROARRAY ANALYSIS; NON INVASIVE PROCEDURE; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 84864666526     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Walsh JM and Terdiman JP: Colorectal cancer screening: Scientific review. J Amer Med Assoc 289: 1288-1896, 2003.
2. Collins JF, Lieberman DA, Durbin TE and Weiss DG: Accuracy of screening for fecal occult blood on a single sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 142: 81-85, 2005.
3. Mandel JS: Screening for colorectal cancer. Gastroenterol Clin N Amer 37: 97-115, 2008.
4. Senore C, Ederle A, Fantin A, Andreoni B, Bisanti L, Grazzini G, Zappa M, Ferrero F, Maratti A, Giutiani O, Armadi P and Segnan N: Acceptability and side-effects of colonoscopy and sigmoido-scopy in a screening setting. J Med Screening 18: 128-134, 2011.
5. Ng EKO, Chong WWS, Jin H, Lam EKY, Shin VY, Yu J, Poon TCW, Ng SSM and Sung JJY: Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 58: 1375-1381, 2009.
6. Davies RJ, Miller R and Coleman N: Colorectal cancer screening: Prospects for molecular stool analysis. Nature Rev Cancer 5: 199-20, 2005.
7. Peterson NB, Murff HJ, Ness RM and Dittus RS: Colorectal cancer screening among men and women in the United States. J. Womens Health 16: 57-65, 2007.
8. Centers for Disease Control and Prevention: Increased use of colorectal cancer test: United States, 2002 and 2004, MMWR Mortal Wkly 55: 208-311, 2006.
9. Bressler B, Paszat LF, Vinden C, Li C, He J and Rabeneck L: Colonoscopic miss rates for right-sided colon cancer: Population-based study. Gastroenterology 127: 452-456, 2004. (Pubitemid 39091893)
10. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut A I: Risk of perforation after colonoscopy and sigmoidoscopy: A population based study. J Natl Cancer Inst 95: 230-236, 2002.
11. Ahmed FE: The role of microRNA in carcinogenesis and biomarker selection: A methodological perspective. Exp Rev Mol Diag 7: 569-603, 2007.
12. Lewis BP, Burge CB and Bartel DP: Conserved seed paring, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
13. Reinhart BJ, Slack FJ, Basson M, Pasquinell AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000. (Pubitemid 30130993)
14. Xu P, Guo M and Hay BA: MicroRNAs and the regulation of cell death. Trend Genet 20: 617-624, 2004. (Pubitemid 39441280)
15. Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512, 2005. (Pubitemid 40616320)
16. Cummins JM and Velculescu VE: Implication of microRNA profiling for cancer diagnosis. Oncogene 15: 6220-6227, 2006. (Pubitemid 44527853)
17. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner M, Frankel WL, Morgan DL, Positer RG, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Neaci T, Calin GA, Querzoli P, Negrini M and Croce CM: Expression profiling identifies distinct microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007. (Pubitemid 46214304)
18. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamota A, Yokota J, Tanaka T, Galin GA, Liu CG, Groce CM and Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006. (Pubitemid 43357945)
19. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Margri E, Pedriali M and Fabbri M: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005. (Pubitemid 41161233)
20. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr., Sjoblom T, Barad O, Benturch Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Kinzler KW, Juhl H, Vogelstein B and Velculescu VE: The colorectal microRNome. Proc Natl Acad Sci USA 103: 3687-3692, 2006.
21. Calin GA, Ferracin M, Cimmino A, Dileva G, Shimiz M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Ludiano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Adler H, Volinia S, Liu CG, Kipps TJ, Negrini M and Croce CM: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Eng J Med 353: 1793-1801, 2005. (Pubitemid 41549891)
22. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B-cell lymphomas. Proc Natl Acad Sci USA 102: 3627-3632, 2003.
23. Chang-Zheng C: MicroRNAs as oncogenes and tumor supressors. N Eng J Med 353: 1768-1771, 2005.
24. Calin GA, Sevignai C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004. (Pubitemid 38327724)
25. Schepler T, Reinert JT, Oslenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S, Kauppinen S, Ørntoft T and Andersen CL: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424, 2008.
26. Barbarotto E, Schmittgen TD and Calin GA: MicroRNAs and cancer: Profile, profile, profile. Int J Cancer 122: 969-977, 2008. (Pubitemid 351213993)
27. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TS, Kwong DLW, Au GKH, Liu CG, Calin GA and Harris CC: MicroRNA expression profile associated with progression and therapeutic outcome in colon adenocarcinoma. J Am Med Assoc 299: 425-436, 2008. (Pubitemid 351185951)
28. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
29. Kozomara A and Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39 (Suppl 1): D152-D157, 2011.
30. Morikawa T, Kato J, Yamaji, Wada R, Miksushima T and Shiratori Y: Comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 125: 422-428, 2006. (Pubitemid 41096630)
31. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC III, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S and Shuber A: Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 5: 111-117, 2007. (Pubitemid 46096834)
32. Huang LH, Li LH, Yang F and Wang JF: Detection of aberrant methylation in fecal DNA s a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 13: 950-954, 2007. (Pubitemid 46470311)
33. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, Lamerz R and Kolligs FT: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 3: 142-149, 2005. (Pubitemid 40220309)
34. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN and Shuber AP: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119: 1219-1227, 2000.
35. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr., Hamilton SR, Boynton K, Kinzler KW and Vogelstein B: Detection of APC mutations in fecal and DNA from patients with colorectal tumors. N Engl J Med 346: 311-320, 2002. (Pubitemid 34438838)
36. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross MA: Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. New Eng J Med 351: 2704-2714, 2004. (Pubitemid 39665324)
37. Ahmed FE: Liquid chromatography-mass spectrometry: A tool for proteome analysis and biomarker discovery and validation. Exp Opin Mol Diag 3: 429-444, 2009.
38. Sobin LH and Wittekind CH (eds.): UICC TNM Classification of Malignant Tumors, 6th Edition. New York, John Wiley,170-173, 2002.
39. Greene FL, Page DL and Fleming ID (eds.). AJCC Cancer Staging Manual. 6th Edition. Springer-Verlag, New York, 2002.
40. Deschner EE: Early proliferative changes in gastrointestinal neoplasia. Am J Gastroenterol 77: 207-211, 1982.
41. Ahmed FE: Laser microdissection: application to carcinogenesis. Cancer Genom Proteom 3: 217-226, 2006.
42. Nair P, Lagerholm S, Dutta S, Shami, S, Davis K, Ma S and Malayeri M: On the nature of cellular elements from stool in the pathophysiology of colonic disease. J Clin Gastroenterol 36(Suppl 1): 584-590, 2003.
43. Ahmed F E, iJames S, Lysle DL, Dobbs LJ Jr, Johnke RM, Flake G, Stockton P, Sinar DR, Naziri W, Evans MJ, Kovacs CJ and Allison R: Improved methods for extracting RNA from exfoliated human colonocytes in stool and RT-PCR analysis. Dig Dis Sci 49: 1889-1898, 2004.
44. Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, Naziri W and Marcuard SP: Diagnostic microRNA markers for screening sporadic human colon cancer and ulcerative colitis in stool and tissue. Cancer Genom Proteom 6: 281-296, 2009.
45. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ and Guegler KJ: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
46. Liu CG, Callin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupos S, Dono M, Alder H, Bullrich F, Negrini M and Croce CM: An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 101: 9740-9744, 2004. (Pubitemid 38869306)
47. Ahmed FE: Microarray RNA transcriptional profiling: Part II. Analytical considerations and annotations. Exp Rev Mol Diag 6: 736-750, 2006.
48. Huber W, von Heydebreck A, Sültmann M, Poustka A and Vingron M: Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18: S96-S104, 2002. (Pubitemid 41185642)
49. Drãghici S: Data Analysis Tools for DNA Mcroarrays. Boca Raton, FL, Chapman/CRC, 2003.
50. Pavlidis P: Using ANOVA for gene selection from microarray studies of the nervous system. Methods 31: 282-289, 2003.
51. Benjamini Y and Hochberger Y: Controlling false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 57: 289-300, 1995.
52. Ahmed FE, Vos PW, Jeffries C, Wiley J, Weidner DA, Mota H, Bonnerup C, Sibata C and Allison RR: Differences in mRNA and microRNA expression profiles in human colon adenocarcinoma HT-29 cells treated with either intensity-modulated radiation therapy (IMRT), or conventional radiation therapy (RT). Cancer Genom Proteom 6: 109-128, 2009.
53. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS and Chen C: Real-time PCR quantification of precursor and mature microRNA. Methods 44: 31-38, 2008. (Pubitemid 350297984)
54. Lee EJ and Schmittgen TD: Comparison of RHA assay methods used to normalize cDNA for quantitative real time PCR. Anal Biochem 357: 299-301, 2006. (Pubitemid 44415685)
55. Tellman G: The E-method: A highly accurate technique for gene expression analysis. Nature Methods 3: 1-11, 2006.
56. LightCycler Software®, Version 3.5. Roche Molecular Biochemicals, Manneheim, Germany, pp. 64-79, 2001.
57. Pfaffl MW: Quantification strategies in real-time PCR. In: A-Z of Quantitative PCR. Bustin SA (ed.). La Jolla, CA, International University Line, pp. 89-120, 2004.
58. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔt method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
59. Ahmed FE: Quantitative real-time RT-PCR: Application to carcinogenesis. Cancer Genom Proteo 2: 317-332, 2005.
60. Bustin SA, Ed: A-Z of Quantitative PCR. International University Line, La Jolla, CA, 2004.
61. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G and van Dongen JJ: Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17: 2318-2357, 2003. (Pubitemid 38072573)
62. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesomplete J and Wittwer CT: The MIQUE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622, 2009.
63. Ahmed FE: Effect of diet, life style, and other environmental/ chemopreventive factors on colorectal cancer development, and assessment of the risks. J Environ Sci Health C22: 91-147, 2004.
64. Rifai N, Gillette MA andCarr, SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechol 24: 971-983, 2006. (Pubitemid 44215392)
65. Oberg AL, French AJ, French AJ, Sarver AL, Subramanian S, Morlan BW, Riska SM, Borralho PM, Cunningham JM, Boardman LA, Wang L, Smyrk TS, Asmann Y, Steer CJ and Thibodeau SN: miRNA expression in colon polyps provide evidence for a multihit model of colon cancer. PLoS ONE 6: e20465, 2011
66. Ahmed FE, Vos P, iJames S, Lysle DT, Allison RR, Flake G, Sinar DR, Naziri W, Marcuard SP and Pennington R: Transcriptomic molecular markers for screening human colon cancer in stool and tissue. Cancer Genom Proteom 4: 1-20, 2007.
67. Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, Dominguez G, Provencio M, Espana P and Bonilla F: Detection of epithelial tumor RNA in the plasma of colon cancer patients is associated with advanced stage and circulating tumor cells. Gut 50: 530-534, 2002. (Pubitemid 34638874)
68. Ng EK, Tsui NB, Lam NY, Chile RWK, Yu SCH, Wong SCC, Lo ESF, Rainer TH, Johnson PJ and Lo YMD: Presence of filterable and nonfiltirable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 48: 202-207, 2002.
69. Wong SC, Lo SF, Cheung MT, Ng KOE, Tse CW, Lai PSP, Lee KC and Lo YMD: Quantification of plasma beta-catenin miRNA in colorectal cancer and adenoma patients. Clin Cancer Res 10: 1613-1617, 2004. (Pubitemid 38435550)
70. Corte H, Manceau G, Blons H and Laurent-Puig P: MicroRNA and colorectal cancer. Dig Liver Dis 44: 195-200, 2012.
71. Turchinovich A, Weiz L, Langheinz A and Burwinkel B: Characterization of extracellular circulating microRNA. Nucleic Acids Res 39: 7223-7233, 2011.
72. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Dreschen CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella R, Nelson PS, Martin DB and Tawari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
73. Kosaka N, Iguchi H and Ochiyn T: Circulating microRNA in bodyfluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092, 2010.
74. Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtypes. Genes Chromo Cancer 50: 196-206, 2011.
75. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bendnarikova M, Nenuti LR and Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathology features of colorectal cancer. Oncology 72: 397-402, 2007. (Pubitemid 351238155)
76. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118-126, 2009.
77. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tan Y and Lin TY: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker for colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25: 1674-1680, 2010.
78. Koga Y, Yasanaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H and Natsamura Y: MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res 3: 1435-1442, 2010.
79. de Krijger I, Mekenkamp JM, Punt CHA and Nagtegaal ID: miRNAs in colorectal cancer mtatstases. J Pathol 224: 438-447, 2011.
80. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KAT, Morlan BW, Riska SM, Bordman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CMP, Thibodeau SN and Steer CJ: Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401, 2009.
81. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and underexpressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
82. Lanza G, Ferrracin M, Gafa R, Veronesse A, Spizzo R, Pichiorri F, Liu CG, Calin GA, Croce CM and Negrini M: mRNA/miRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 6: 54, 2007.
83. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and García- Foncillas J: Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumor tissues. Mol Cancer 5: 29, 2006.
84. Liu M and Chen H: The role of microRNAs in colorectal cancer. J Genet Genomics 37: 347-358, 2010.
85. Arndt GM, Dossey L, Cullen L, Lai A, Druker R, Eisenbacher M, Zhang C, Tran N, Ean H, Retzlaff K, Bittner A and Raponi M: Characterisation of global microRNA expression reveals oncogenic potential of miR-145 in metabolic colorectal cancer. BMC Cancer 9: 374, 2009.
86. Huang ZM, Yang J, Shen XY, Zhang XY, Meng FS, Xu JT, Zhang BF and Gao HJ: MicroRNA expression profile in non-cancerous colonic tissue associated with lymph node metastasis of colon cancer. J Dig Dis 10: 188-194, 2009.
87. Schimanski CC, Freichs K, Rahman F, Berger M, Lang H, Gable PR, Moehler M and Gockel I: High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 15: 2089-2096, 2009.
88. Wang CJ, Zhan ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY and Sun XF: Clinicopathological significance of miRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 26: 27-34, 2009.
89. Wittmann J and Jäck HM: Serum microRNAs are powerful cancer biomarkers. Biochimica Biophysica Acta 1806: 200-207, 2010.
90. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising normal biomarkers for early definition of colorectal cancer. Int J Cancer 127: 118-126, 2010.
91. Agostini M, Pucciarelli S, Calore F, Bedir C, Enzo M and Nitti D: miRNAs in colon and rectal cancer: A consensus for their true clinical value. Clinica Chimica Acta 411: 1180-1186, 2010.
92. Aslam MI, Taylor K, Pringle JH and Jameson JS: MicroRNAs are novel biomarkers of colorectal cancer. Br J Surgery 96: 702-710, 2009.
93. Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ and Kerin MJ: MicroRNA signature analysis in colorectal cancer: Identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 26: 1415-1422, 2011.
94. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11: 50-54, 2010.
95. Pepe M S, Feng Z, Janes H, Bossuyt PM and Potter JD: Pivotal evaluation of the occurance of a biomarker used for classification or prediction: Standards for study design. of Cancer. J Natl Cancer Inst 100: 1432-1438, 2008.